Author

D. T. Weaver

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Evolutionary Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Organism:E. coli· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

E. S. King· 2 shared J. G. Scott· 2 shared A. E. Stacy· 1 shared A. M. Barrie· 1 shared A. M. Mark· 1 shared A. Molinolo· 1 shared B. Gyorffy· 1 shared C. J. Diaz Osterman· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

E. S. King

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Reinforcement Learning informs optimal treatment strategies to limit antibiotic resistance.

D. T. Weaver, E. S. King, J. Maltas, J. G. Scott

This study uses reinforcement learning to develop optimal antibiotic treatment strategies that reduce antimicrobial resistance in simulated E. coli populations.

bioRxiv · Jan 12, 2023Microbiology

Fitness seascapes are necessary for realistic modeling of the evolutionary response to drug therapy

E. S. King, A. E. Stacy, D. T. Weaver, J. A. Maltas, R. Barker-Clarke, E. Dolson, J. G. Scott

The paper introduces a fitness seascape model to study drug resistance in E. coli by mapping genotypes to dose-response functions and shows that higher mutation supply and early drug adherence reduce resistance.

bioRxiv · Jun 10, 2022Evolutionary Biology

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

C. J. Diaz Osterman, D. Ozmadenci, E. G. Kleinschmidt, K. N. Taylor, A. M. Barrie, S. Jiang, L. M. Bean, F. J. Sulzmaier, C. Jean, I. Tancioni, K. Anderson, S. Uryu, E. A. Cordasco, J. Li, X. L. Chen, , D. D. Schlaepfer

This study identifies FAK activity as a driver of platinum resistance in ovarian cancer by sustaining CSC survival and DNA repair, showing that FAK inhibitors combined with platinum can overcome resistance.

bioRxiv · Mar 30, 2019Cancer Biology